Tests tirofiban for late stroke guided by detailed brain vessel imaging
Tests tirofiban in adults with stroke caused by narrowed brain arteries, treated late.
Plain-language title generated from the registry record
Registry title: HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)
Key facts
- Where
- Weifang, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a stroke in the front part of the brain who arrive late, more than 24 hours and up to 7 days after symptoms began. A special MRI scan must show the stroke is caused by narrowing of a large artery inside the skull.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Acute ischemic stroke in the anterior circulation (internal carotid artery system), more than 24 hours and up to 7 days after symptoms began. Stroke severity score (NIHSS) of 4-20. Cause confirmed as intracranial large artery atherosclerosis by high-resolution vessel wall imaging.
- Earlier treatment
- Must not be planned to receive reperfusion therapy (endovascular therapy or intravenous thrombolysis).
- Biomarker or test result
- High-resolution vessel wall MRI (HR-VWI) must confirm the stroke is caused by intracranial large artery atherosclerosis, with a heart-related clot and other causes ruled out.
Main reasons for not taking part
- Bleeding in the brain seen on CT
- Definite or suspected heart-related clot, or atrial fibrillation
- Stroke caused by other conditions such as Moyamoya disease, arterial dissection or arteritis
- Cannot take blood-thinning (antiplatelet) medicine, has bleeding disorders, or is allergic to aspirin
- Malignant tumour, chronic hemodialysis, or severe kidney, liver or heart failure
Read by machine on 9 November 2026.
Where in China
- Weifang People's HospitalWeifang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Weifang Medical University
- Trial code
- NCT07379190
- Record updated
- 25 June 2026
- Original description
This study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time window. HR-MRI allows clear visualization of intracranial arterial wall structures and direct identification of key pathological features of the culprit vessel, including atherosclerotic plaques, vascular wall remodeling, and intracranial hemorrhage, thereby enabling reliable differentiation between intracranial atherosclerotic large artery atherosclerosis (ICAS-LAA) stroke and other etiological subtypes such as cardiogenic embolism. Based on the latest clinical demands and advances in imaging technology, this study intends to evaluate the efficacy and safety of tirofiban in patients with ICAS-LAA stroke beyond the time window under the precise guidance of HR-MRI. It is expected to provide high-level evidence-based medical evidence for this specific patient population and further optimize clinical diagnosis and treatment strategies.Read full original descriptionShow less
Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging
This study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time window. HR-MRI allows clear visualization of intracranial arterial wall structures and direct identification of key pathological features of the culprit vessel, including atherosclerotic plaques, vascular wall remodeling, and intracranial hemorrhage, thereby enabling reliable differentiation between intracranial atherosclerotic large artery atherosclerosis (ICAS-LAA) stroke and other etiological subtypes such as cardiogenic embolism. Based on the latest clinical demands and advances in imaging technology, this study intends to evaluate the efficacy and safety of tirofiban in patients with ICAS-LAA stroke beyond the time window under the precise guidance of HR-MRI. It is expected to provide high-level evidence-based medical evidence for this specific patient population and further optimize clinical diagnosis and treatment strategies.
Inclusion: Age ≥ 18 years old; Acute ischemic stroke (AIS) in the anterior intracranial circulation (internal carotid artery system) confirmed by clinical symptoms and imaging examinations; Time from symptom onset or last known normal state to randomization: > 24 hours and ≤ 7 days; Stroke subtype confirmed as intracranial large artery atherosclerosis (ICAS) by high-resolution vessel wall imaging (HR-VWI) according to the TOAST classification, with cardiogenic embolism and other etiologies excluded; Baseline National Institutes of Health Stroke Scale (NIHSS) score of 4-20 at the time of randomization; Signed informed consent form obtained from the patient or their legal representative.
Exclusion: Planned to receive reperfusion therapy (endovascular therapy or intravenous thrombolysis)；; Concurrent new cerebral infarction in both anterior and posterior circulations; Concurrent participation in other therapeutic clinical trials with incomplete treatment and follow-up; Intracranial hemorrhage confirmed by computed tomography (CT)；; History of atrial fibrillation or current electrocardiogram indicating atrial fibrillation；; Acute ischemic stroke caused by other etiologies, such as Moyamoya disease, arterial dissection, arteritis, etc；; Known contraindications to antiplatelet therapy, including hematochezia, gastrointestinal bleeding, or any other hemorrhagic disorders; History of hypersensitivity to aspirin; Definite indication for anticoagulant therapy expected during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state, etc.); Severe heart failure (New York Heart Association [NYHA] Functional Classification Class III or IV); Presence of other known neurological disorders that may complicate the follow-up; Other conditions that the investigators consider inappropriate for enrollment in this study; Complicated with malignant tumors, chronic hemodialysis, severe renal insufficiency (glomerular filtration rate [GFR] < 30 ml/min or serum creatinine [Cr] > 220 μmol/L (2.5 mg/dl)), or severe hepatic insufficiency (serum alanine aminotransferase [ALT] > 2 times the upper limit of normal [ULN], or serum aspartate aminotransferase [AST] > 2 times the ULN); Definite or suspected cardiogenic embolism；; Imaging examinations indicating that the area of the current cerebral infarction exceeds 1/2 of the area of a single cerebral lobe; Complicated with severe non-cardiovascular comorbidities, with an estimated survival time < 6 months; Inability to complete the follow-up procedures.